Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Gaush Meditech Ltd. ( (HK:2407) ) has shared an announcement.
Gaush Meditech Ltd reported a revenue increase of 1.6% for the year ending December 31, 2024, reaching RMB1,428.4 million. However, the company’s net profit dropped significantly by 48.8% to RMB88.5 million, attributed to increased costs and expenses. The board has proposed a final dividend of HK$0.3 per share, pending shareholder approval, reflecting a decrease from the previous year’s HK$1.1 per share. This financial performance indicates challenges in maintaining profitability despite revenue growth, potentially impacting shareholder returns and market positioning.
More about Gaush Meditech Ltd.
Gaush Meditech Ltd, incorporated in the Cayman Islands, operates within the medical technology industry. The company focuses on developing and providing innovative medical devices and solutions.
YTD Price Performance: -38.35%
Average Trading Volume: 476,838
Technical Sentiment Signal: Buy
Current Market Cap: HK$896.2M
Find detailed analytics on 2407 stock on TipRanks’ Stock Analysis page.